ACCENDRA HEALTH INC/VA/(ACH)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,497 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ACH Stock Analysis & AI Quality Score
AI stock analysis and institutional research for ACCENDRA HEALTH INC/VA/ (ACH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ACH at 26.6/100 on a 32-signal composite quality model, placing it at rank #2,497 of 2,879 stocks — the bottom half of the AI-ranked universe. ACH scores in the top quartile across revenue scale (83.3). Areas of concern include revenue growth (1.1) and balance sheet strength (4.3), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), ACCENDRA HEALTH INC/VA/ reports quarterly revenue of $627.8M, net income of $-6.5M, an operating margin of 2.7%. Top institutional holders of ACH by reported 13-F value include Coliseum Capital Management,, BlackRock,, CHARLES SCHWAB INVESTMENT MANAGEMENT, based on the most recent SEC filings. ACH trades on the NYSE exchange and files with the SEC under CIK 75252. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ACH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ACCENDRA HEALTH INC/VA/ directly from SEC EDGAR. ACCENDRA HEALTH INC/VA/'s 13F Pro composite quality score has ranged between 27 and 47 since 2026, currently 26.6 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.
Revenue
Q1 2026
$627.8M
Net Income
Q1 2026
$-6.5M
Free Cash Flow
Q1 2026
$-91.7M
Operating Margin
Q1 2026
2.7%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+5.0% YoYNet Income
-778.2% YoYOperating Income
-263.4% YoYEPS (Diluted)
-792.5% YoYTotal Assets
-8.6% YoYTotal Debt
-12.2% YoYOp. Cash Flow
-78.2% YoY| Metric | FY 2024 | FY 2023 | FY 2021 | FY 2020 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $2.68B +5.0% | $2.55B -73.9% | $9.79B +15.4% | $8.48B -10.0% | $9.42B +1.1% | $9.32B |
| Net Income | $-362.7M -778.2% | $-41.3M -118.6% | $221.6M +641.8% | $29.9M +106.8% | $-437.0M -700.3% | $72.8M |
| Operating Income | $-217.7M -263.4% | $133.2M -63.8% | $368.5M +80.5% | $204.1M +157.9% | $-352.3M -494.8% | $89.3M |
| EPS (Diluted) | $-4.73 -792.5% | $-0.53 -118.0% | $2.94 +525.5% | $0.47 | — | — |
| Total Assets | $4.66B -8.6% | $5.09B +44.0% | $3.54B +6.0% | $3.34B -11.6% | $3.77B +11.8% | $3.38B |
| Total Debt | $1.84B -12.2% | $2.10B +121.4% | $947.5M -11.1% | $1.07B -37.5% | $1.71B +82.6% | $934.0M |
| Operating Cash Flow | $161.5M -78.2% | $740.7M +496.5% | $124.2M -63.4% | $339.2M +193.5% | $115.6M +103.6% | $56.8M |
AI Insight: ACH Financial Trends
Accendra Health's equity has turned deeply negative (-$465M) as cumulative net losses erode the balance sheet, even as operating income stabilizes near breakeven.
• Equity collapsed from $861M in Q2 2024 to -$465M in Q1 2026, driven by persistent net losses every quarter.
• Operating income has stabilized: after a severe -$273M trough in Q4 2024, it recovered to $17M–$26M range in Q3 2025 through Q1 2026.
• Total debt rose from $1,851M in Q4 2024 to $2,103M in Q1 2026, reversing prior deleveraging progress.
• Operating cash flow has been volatile and negative in two of the last four reported quarters (-$35M Q1 2025, -$173M Q3 2025).
⚠ Negative equity of -$465M with rising debt signals potential covenant risk; balance sheet deterioration warrants close monitoring.
⚠ Q2 2025 net loss of -$869M was an extreme outlier — nature and recurrence of that charge is a key risk to clarify.
⚠ Revenue data is missing for Q3 2024, Q2 2025, and recent quarters, limiting visibility into top-line trajectory.
AI Insight: ACH Ratio Trends
ROIC recovering to 4.2% in Q1 2026 after a severe -44.8% collapse in Q4 2024, but persistent negative net margins signal profitability remains fragile.
• ROIC rebounded from -44.8% in Q4 2024 to 4.2% in Q1 2026, recovering through three consecutive positive quarters.
• Net profit margin improved from -42.6% in Q4 2024 to -1.0% in Q1 2026, though still negative throughout the entire period.
• ROA deteriorated sharply to -83.7% in Q2 2025 before recovering to -1.1% in Q1 2026, indicating significant asset-level volatility.
⚠ D/E ratio rose from 2.42 in Q2 2024 to 3.41 in Q1 2025 — last reported — signaling increasing leverage pressure.
⚠ Operating margin remains thin at 2.7% in Q1 2026; any revenue softness could quickly push it back negative.
⚠ Persistent gap between operating margin (2.7%) and net margin (-1.0%) in Q1 2026 suggests meaningful below-the-line costs to monitor.
Get alerted when ACH's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ACCENDRA HEALTH INC/VA/ including:
Top Institutional Holders of ACH
Coliseum Capital Management, LLC
$29.9M13,100,807 shBlackRock, Inc.
$11.9M5,235,300 shCHARLES SCHWAB INVESTMENT MANAGEMENT INC
$8.3M3,635,526 shBANK OF AMERICA CORP /DE/
$7.8M3,407,075 shInvenomic Capital Management LP
$7.7M3,368,975 shD. E. Shaw & Co., Inc.
$7.6M3,311,601 shVANGUARD CAPITAL MANAGEMENT LLC
$7.5M3,282,174 shVANGUARD PORTFOLIO MANAGEMENT LLC
$6.0M2,651,152 shDIMENSIONAL FUND ADVISORS LP
$5.9M2,606,620 shGEODE CAPITAL MANAGEMENT, LLC
$4.2M1,835,910 sh
| Fund | Value | Shares |
|---|---|---|
| Coliseum Capital Management, LLC | $29.9M | 13,100,807 |
| BlackRock, Inc. | $11.9M | 5,235,300 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $8.3M | 3,635,526 |
| BANK OF AMERICA CORP /DE/ | $7.8M | 3,407,075 |
| Invenomic Capital Management LP | $7.7M | 3,368,975 |
| D. E. Shaw & Co., Inc. | $7.6M | 3,311,601 |
| VANGUARD CAPITAL MANAGEMENT LLC | $7.5M | 3,282,174 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $6.0M | 2,651,152 |
| DIMENSIONAL FUND ADVISORS LP | $5.9M | 2,606,620 |
| GEODE CAPITAL MANAGEMENT, LLC | $4.2M | 1,835,910 |
More Healthcare Companies
View all Healthcare →Put ACH on your watchlist
Track score changes the day ACCENDRA HEALTH INC/VA/ files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ACH a good stock to buy?
13F Pro's AI-powered analysis of ACCENDRA HEALTH INC/VA/ (ACH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ACH are available on the ACH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ACH?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ACH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ACCENDRA HEALTH INC/VA/'s investment landscape.